Dificid's Efficacy and Actions
Dificid was developed by Astellas Pharma in Japan and approved by the US FDA on May 27, 2011.
Dificid is a fermentation product obtained from the actinomycete *Dactylosporangium aurantiacum*. It is a macrolide antibiotic that inhibits RNA synthesis by binding to RNA polymerase.
Dificid exhibits bactericidal activity against *Clostridium difficile* in vitro, showing a post-antibacterial effect of 6-10 hours.
Dificid's Indications
1. Indications
For the treatment of *Clostridium difficile*-associated diarrhea (CDAD) in adults and children aged 6 months and older.
2. Population Indications
Adults and children aged 6 months to 18 years, for confirmed or highly suspected infections caused by *Clostridium difficile*.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of difacic acid and other antimicrobial agents, difacic acid should only be used to treat infections proven or strongly suspected to be caused by Clostridium difficile.
Difacic Acid (Dificid) Dosage and Administration
1. Standard Adult Dose
200 mg twice daily for 10 consecutive days.
2. Timing of Administration
Difacic acid is not affected by food and can be taken with or without food, according to the patient's preference.
Difacic Acid (Dificid) Precautions
1. There have been reports of acute allergic reactions (angioedema, dyspnea, itching, and rash). If a severe allergic reaction occurs, difacic acid should be discontinued.
2. Due to the minimal systemic absorption of difacic acid, it is expected to be ineffective in treating other types of infections. Difacic acid should only be used to treat Clostridium difficile-associated diarrhea.
3. Difacic acid should only be used for infections proven or strongly suspected to be caused by Clostridium difficile.
Adverse Reactions/Side Effects of Dificid (Fridamycin)
1. The most common adverse reactions in adults (incidence ≥2%) include: nausea, vomiting, abdominal pain, gastrointestinal bleeding, anemia, and neutropenia.
2. The most common adverse reactions in pediatric patients treated with dificid (incidence ≥5%) include: fever, abdominal pain, vomiting, diarrhea, constipation, elevated transaminases, and rash.
Special Populations for Dificid Use
1. Pregnant Women
Data on the use of dificid are limited, but animal studies have not shown significant harm to the fetus. Use should be based on a risk-benefit analysis.
2. Lactating Women
Caution is advised when using this medication, as it is currently unknown whether dificid passes into breast milk.
3. Elderly Patients
No dose adjustment is required. Studies have shown slightly higher blood concentrations in the elderly than in younger patients, but this is not clinically significant.
4. Patients with Renal or Hepatic Impairment
No dose adjustment is required either, as the drug is hardly metabolized by the kidneys or liver.
